Journal
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
Volume 13, Issue 3, Pages 221-231Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10837450801949566
Keywords
dry eye; ocular insert; alginates; EGF
Categories
Ask authors/readers for more resources
We developed and tested ocular inserts containing epidermal growth factor (EGF) for a causal treatment of keratoconjunctivitis sicca (KCS). The inserts, consisting of different alginates with hydroxyethylcellulose (HEC) as a lubricant and release modifier, released EGF over time periods ranging from a few hours up to several days. The stability of EGF was high, having a protein half-life of approximately 548 days. A clinical pilot study suggests an amelioration of both the main symptoms and the objective criteria: tear film break-up (BUT) time and lissamine green score. Our results show that EGF treatment of KCS is highly promising.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available